Quick facts
- Class
- α-MSH (melanocortin) analog
- Brand name
- Scenesse
- Approved for
- Erythropoietic protoporphyria (EPP)
- Evidence level
- Phase 3 randomized trials
- Status
- FDA-approved, prescription/implant-administered
- Class
- Synthetic alpha-MSH analog (melanocortin receptor agonist)
- Approval status
- FDA- and EMA-approved for erythropoietic protoporphyria
- Brand name
- Scenesse
- Route
- Subcutaneous implant placed by a clinician
Key takeaways
- Afamelanotide (sometimes called Melanotan I, brand name Scenesse) is a synthetic analog of alpha-melanocyte-stimulating hormone.
- It is FDA- and EMA-approved to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare inherited light-sensitivity disorder.
- It is administered as a biodegradable implant placed under the skin by a healthcare professional, not as a self-injected or over-the-counter product.
- By stimulating eumelanin production, it provides photoprotection that reduces phototoxic pain reactions in affected patients.
- It is a prescription drug for a specific medical condition and is not approved or intended for cosmetic tanning.
Overview
Afamelanotide, marketed as Scenesse, is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It is sometimes referred to as Melanotan I, though this name has caused confusion with unregulated tanning products sold online. Afamelanotide is a legitimate, regulated pharmaceutical delivered as a clinician-administered subcutaneous implant, and it should not be conflated with the gray-market injectable peptides marketed for cosmetic tanning.
The drug is approved by both the U.S. Food and Drug Administration and the European Medicines Agency for erythropoietic protoporphyria (EPP), a rare inherited disorder in which patients accumulate a light-sensitive compound called protoporphyrin IX. People with EPP experience severe, painful phototoxic reactions after even brief sun exposure, which can profoundly limit daily life. Afamelanotide increases skin pigmentation to reduce this sensitivity.
Its development by Clinuvel Pharmaceuticals represents one of the few examples of a melanocortin peptide reaching full regulatory approval for a medical indication, distinguishing it sharply from the many research-grade peptides that remain investigational or illicit.
How it works
Afamelanotide acts as an agonist at the melanocortin-1 receptor (MC1R), which is found on the surface of pigment-producing cells called melanocytes. By binding this receptor, the peptide stimulates the production of eumelanin, the darker form of melanin. The result is increased skin pigmentation independent of ultraviolet light exposure, effectively producing a protective tan-like response without requiring sun damage to trigger it.
In erythropoietic protoporphyria, the elevated melanin provides a physical and biochemical shield. Melanin absorbs and scatters visible and ultraviolet light, reducing the energy reaching the accumulated protoporphyrin IX that drives painful phototoxic reactions. This allows patients to tolerate substantially more light exposure before symptoms appear.
Compared with natural alpha-MSH, afamelanotide is engineered for greater potency and a longer duration of action, which is why it can be administered as a slow-release implant lasting roughly two months. Beyond pigmentation, melanocortin receptor activation has been studied for potential antioxidant and anti-inflammatory effects, though in the approved EPP setting the photoprotective pigmentation pathway is the central mechanism of clinical benefit.
Clinical evidence
Afamelanotide's approval for erythropoietic protoporphyria was supported by randomized, placebo-controlled clinical trials conducted across multiple sites in Europe and the United States. These studies measured how long patients could spend in sunlight without pain and assessed overall quality-of-life outcomes, since the disease's burden is heavily tied to avoidance of daylight. Trial participants receiving the implant generally reported more pain-free time in direct sunlight than those receiving placebo.
The European Medicines Agency granted marketing authorization in 2014, and the FDA followed with approval in 2019, making it the first approved therapy specifically for EPP. Post-authorization safety monitoring has continued, in part because EPP is rare and long-term real-world data are valuable for a chronic, repeatedly dosed treatment.
It is worth noting that the evidence base is built around a specific orphan indication. Claims about broader uses, such as vitiligo or general photoprotection, are areas of ongoing or exploratory investigation rather than established, approved benefits. Patients and clinicians should interpret marketing or anecdotal reports of cosmetic or off-label use with caution, as these fall outside the rigorously studied EPP population.
Dosing & side effects
Afamelanotide is administered only by a trained healthcare professional as a small dissolvable implant placed under the skin, typically in a clinical setting. Because it is a prescription implant with a defined release profile and requires medical placement, it is not something patients self-administer, and specific dosing schedules are determined by the treating physician. This guide does not provide dosing protocols; treatment decisions belong with a qualified clinician familiar with the patient's condition.
Reported side effects in clinical use include headache, nausea, fatigue, and reactions at the implant site such as pain or discoloration. Because the drug increases pigmentation broadly, patients may notice darkening of skin, moles, and freckles. For this reason, regular skin examinations are generally recommended so that any changes in pigmented lesions can be monitored.
The unregulated injectable peptides sold online under the Melanotan name are not equivalent to Scenesse and carry distinct risks, including contamination, inaccurate dosing, and reports of changes to moles. Those products are not quality-controlled pharmaceuticals, and their use for tanning is strongly discouraged by dermatology bodies.
Legal status
Afamelanotide, under the brand name Scenesse, holds full regulatory approval for the treatment of erythropoietic protoporphyria. The European Medicines Agency authorized it in 2014, and the U.S. Food and Drug Administration approved it in 2019. In these jurisdictions it is a legitimate prescription medicine available through specialized treatment centers for the approved indication.
It is critical to distinguish the approved implant from unlicensed Melanotan products. The injectable peptides marketed online for cosmetic tanning are not approved by the FDA, the EMA, or comparable regulators, and health authorities in several countries have issued warnings against their sale and use. Purchasing or using those gray-market products carries both legal and safety concerns depending on jurisdiction.
Because afamelanotide is delivered as a clinician-administered implant for a rare disease, access is typically limited to certified providers and may be subject to specific reimbursement and prescribing pathways. Individuals seeking treatment for EPP should consult a physician or specialist center rather than any online vendor, and should not assume that products sharing the Melanotan name are interchangeable with the approved therapy.
Frequently asked questions
What is afamelanotide approved to treat?
Afamelanotide is approved to increase the amount of pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder that causes painful skin reactions to light. It is not approved for general cosmetic tanning.
How is afamelanotide given?
It is supplied as a small biodegradable implant that a healthcare professional inserts under the skin, where it releases the drug over time. It is not self-administered or sold over the counter.
How does afamelanotide work?
It activates melanocortin receptors to increase eumelanin, the skin pigment that absorbs and scatters light. This added pigmentation provides photoprotection that helps reduce phototoxic reactions in people with EPP.
Is afamelanotide the same as Melanotan II?
No. Afamelanotide (Melanotan I) is an approved prescription medicine for a rare disorder, while Melanotan II is an unapproved, unregulated compound sold online. They are different molecules with different uses and safety oversight.
Can afamelanotide be used for cosmetic tanning?
It is approved only for managing light sensitivity in EPP, not for cosmetic purposes. Any non-approved use would fall outside its evaluated indication and clinical oversight.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015. Peer-reviewed study
- Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015. Peer-reviewed study
- Polańska A, Wegner J, Nutbohm P, et al. Afamelanotide in protoporphyria and other skin diseases: a review. Postepy Dermatol Alergol. 2024. Peer-reviewed study
- Wensink D, Wagenmakers MAEM, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2021. Peer-reviewed study
- Wu J, Cotliar R. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. J Drugs Dermatol. 2021. Peer-reviewed study
- Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. Am J Clin Dermatol. 2016. Peer-reviewed study